thalidomide has been researched along with 2019 Novel Coronavirus Disease in 22 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The "Thalidomide tragedy" is a landmark in the history of the pharmaceutical industry." | 7.01 | Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis. ( Alampady, V; Baby, K; Byregowda, BH; Dsouza, NN; Maity, S; Nayak, Y, 2023) |
| "Apremilast is a recently approved drug, belonging to the small molecule phosphodiesterase 4 inhibitors, whose optimal safety and efficacy profile is somewhat affected by slow activity rate in clinical trials." | 5.56 | Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic. ( Atzori, L; Melis, D; Mugheddu, C; Rongioletti, F; Sanna, S, 2020) |
| " Here, we report eight patients with multiple myeloma that underwent immunomodulatory therapies with daratumumab or lenalidomide-based combination treatments and one patient with smoldering multiple myeloma, all of which presented with symptomatic COVID-19." | 3.96 | Outcome of COVID-19 in multiple myeloma patients in relation to treatment. ( Alici, E; Gran, C; Ljunggren, HG; Nahi, H; Susek, KH, 2020) |
| "The "Thalidomide tragedy" is a landmark in the history of the pharmaceutical industry." | 3.01 | Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis. ( Alampady, V; Baby, K; Byregowda, BH; Dsouza, NN; Maity, S; Nayak, Y, 2023) |
| "One hundred four patients (40." | 1.62 | Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. ( Andriulli, A; Bossa, F; Carparelli, S; Corritore, G; D'Altilia, M; Guerra, M; Latiano, A; Latiano, T; Marseglia, A; Martino, G; Nardella, M; Palmieri, O; Panza, A; Pastore, M; Perri, F; Sacco, M; Tavano, F; Terracciano, F, 2021) |
| "Apremilast is a recently approved drug, belonging to the small molecule phosphodiesterase 4 inhibitors, whose optimal safety and efficacy profile is somewhat affected by slow activity rate in clinical trials." | 1.56 | Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic. ( Atzori, L; Melis, D; Mugheddu, C; Rongioletti, F; Sanna, S, 2020) |
| "There is no agreed treatment for cytokine storm." | 1.56 | Alternative management of Covid-19 infection. ( Atrah, HI, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 22 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, SMA | 1 |
| Volontè, M | 1 |
| Isoletta, E | 1 |
| Vassallo, C | 1 |
| Tomasini, CF | 1 |
| Lilleri, D | 1 |
| Zelini, P | 1 |
| Musella, V | 1 |
| Klersy, C | 1 |
| Brazzelli, V | 1 |
| Lytvyn, Y | 1 |
| Georgakopoulos, JR | 1 |
| Mufti, A | 1 |
| Devani, AR | 1 |
| Gooderham, MJ | 1 |
| Jain, V | 1 |
| Lansang, P | 1 |
| Vender, R | 1 |
| Prajapati, VH | 1 |
| Yeung, J | 1 |
| Djebbari, F | 1 |
| Rampotas, A | 1 |
| Vallance, G | 1 |
| Panitsas, F | 1 |
| Basker, N | 1 |
| Sangha, G | 1 |
| Salhan, B | 1 |
| Karim, F | 1 |
| Firas, AK | 1 |
| Gudger, A | 1 |
| Ngu, L | 1 |
| Poynton, M | 1 |
| Lam, HPJ | 1 |
| Morgan, L | 1 |
| Yang, L | 1 |
| Young, J | 1 |
| Walker, M | 1 |
| Tsagkaraki, I | 1 |
| Anderson, L | 1 |
| Chauhan, SR | 1 |
| Maddams, R | 1 |
| Soutar, R | 1 |
| Triantafillou, M | 1 |
| Prideaux, S | 1 |
| Obeidalla, A | 1 |
| Eyre, TA | 1 |
| Bygrave, C | 1 |
| Basu, S | 1 |
| Ramasamy, K | 1 |
| Grimaldi, M | 1 |
| Perino, F | 1 |
| Moretta, G | 1 |
| Antonelli, F | 1 |
| Paradisi, A | 1 |
| Ricci, F | 1 |
| Abeni, D | 1 |
| Didona, B | 1 |
| Fania, L | 1 |
| Wu, JJ | 2 |
| Liu, J | 1 |
| Thatiparthi, A | 1 |
| Martin, A | 1 |
| Egeberg, A | 1 |
| Dsouza, NN | 1 |
| Alampady, V | 1 |
| Baby, K | 1 |
| Maity, S | 1 |
| Byregowda, BH | 1 |
| Nayak, Y | 1 |
| Mugheddu, C | 2 |
| Pizzatti, L | 1 |
| Sanna, S | 2 |
| Atzori, L | 2 |
| Rongioletti, F | 2 |
| Armesto, S | 3 |
| González Vela, C | 3 |
| González López, MA | 2 |
| Olisova, OY | 1 |
| Anpilogova, EM | 1 |
| Svistunova, DA | 1 |
| Melis, D | 1 |
| Queiro Silva, R | 1 |
| Naharro Fernández, C | 2 |
| González-Gay, MA | 2 |
| Atrah, HI | 1 |
| Talamonti, M | 1 |
| Tofani, L | 1 |
| Bianchi, L | 1 |
| Galluzzo, M | 1 |
| Susek, KH | 1 |
| Gran, C | 1 |
| Ljunggren, HG | 1 |
| Alici, E | 1 |
| Nahi, H | 1 |
| Tiscornia, JE | 1 |
| Poggio, TV | 1 |
| Feinsilber, DG | 1 |
| Coleman, AE | 1 |
| Sánchez, J | 1 |
| Illaro, A | 1 |
| Mayorga, J | 1 |
| López Sundh, AE | 1 |
| Palmou, N | 1 |
| Gómez-Fernández, C | 1 |
| Bansal, P | 1 |
| Goyal, A | 1 |
| Cusick, A | 1 |
| Aslam, F | 1 |
| Bossa, F | 1 |
| Carparelli, S | 1 |
| Latiano, A | 1 |
| Palmieri, O | 1 |
| Tavano, F | 1 |
| Panza, A | 1 |
| Pastore, M | 1 |
| Marseglia, A | 1 |
| D'Altilia, M | 1 |
| Latiano, T | 1 |
| Corritore, G | 1 |
| Martino, G | 1 |
| Nardella, M | 1 |
| Guerra, M | 1 |
| Terracciano, F | 1 |
| Sacco, M | 1 |
| Perri, F | 1 |
| Andriulli, A | 1 |
| Sundaresan, L | 1 |
| Giri, S | 1 |
| Singh, H | 1 |
| Chatterjee, S | 1 |
| Kearns, DG | 1 |
| Uppal, S | 1 |
| Chat, VS | 1 |
| Pacifico, A | 1 |
| d'Arino, A | 1 |
| Pigatto, PDM | 1 |
| Malagoli, P | 1 |
| Damiani, G | 1 |
| Cerqueira, SRPS | 1 |
| Deps, PD | 1 |
| Cunha, DV | 1 |
| Bezerra, NVF | 1 |
| Barroso, DH | 1 |
| Pinheiro, ABS | 1 |
| Pillegi, GS | 1 |
| Repsold, TAR | 1 |
| Kurizky, PS | 1 |
| Collin, SM | 1 |
| Gomes, CM | 1 |
1 review available for thalidomide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis.
Topics: COVID-19; Humans; Idiopathic Pulmonary Fibrosis; Inflammation; Lung; Pandemics; Thalidomide; Transfo | 2023 |
21 other studies available for thalidomide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
SARS-CoV-2 serology in patients on biological therapy or apremilast for psoriasis: a study of 93 patients in the Italian red zone.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Therapy; COVID-19; Humans; Psoriasis; SARS-CoV-2 | 2022 |
Incidence and prognosis of COVID-19 in patients with psoriasis on apremilast: a multicentre retrospective cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; COVID-19; Humans; Incidence; Prognosis; Psoriasis; Retrospe | 2022 |
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; COVID-19; C | 2022 |
Cutaneous Rosai-Dorfman disease after Covid 19 vaccination treated with thalidomide.
Topics: COVID-19; COVID-19 Vaccines; Histiocytosis, Sinus; Humans; Skin Diseases; Thalidomide; Vaccination | 2022 |
The risk of COVID-19 in patients with psoriasis: A retrospective cohort study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; COVID-19; Humans; Psoriasis; Retrospective Studies; Thalido | 2022 |
COVID-19 pulmonary infection in erythrodermic psoriatic patient with oligodendroglioma: safety and compatibility of apremilast with critical intensive care management.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Coronavirus Infections; COVID-19; Critical | 2020 |
Opportunistic virus infections in psoriasis patients: The safer alternative of apremilast in the COVID-19 era.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Comorbidity; Coronavirus Infections; COVID | 2020 |
Apremilast as a potential treatment option for COVID-19: No symptoms of infection in a psoriatic patient.
Topics: Arthritis, Psoriatic; Betacoronavirus; Coronavirus Infections; COVID-19; Critical Care; Humans; Infe | 2020 |
Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Coronaviru | 2020 |
COVID-19 patients with psoriasis and psoriatic arthritis on biologic immunosuppressant therapy vs apremilast in North Spain.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antirheumatic Age | 2020 |
Alternative management of Covid-19 infection.
Topics: Administration, Intravenous; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatm | 2020 |
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Factors; Clinical Decision-Making; Comorbidity; | 2021 |
Outcome of COVID-19 in multiple myeloma patients in relation to treatment.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Cohort Stud | 2020 |
Thalidomide Should Be Tested as a Therapeutic Option in COVID-19 Pneumonia.
Topics: Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans | 2020 |
Treating multidrug-resistant psoriasis with brodalumab, apremilast, methotrexate and prednisone combination therapy in the COVID-19 pandemic.
Topics: Adult; Antibodies, Monoclonal, Humanized; COVID-19; Drug Resistance, Multiple; Drug Therapy, Combina | 2020 |
Use of Apremilast in Patients With Psoriatic Arthritis During the COVID-19 Pandemic: Comment on the Article by Mikuls et al.
Topics: Adult; Arthritis, Psoriatic; COVID-19; Humans; Pandemics; Rheumatic Diseases; Rheumatology; SARS-CoV | 2021 |
Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs.
Topics: Adalimumab; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclon | 2021 |
Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action.
Topics: COVID-19; Drug Repositioning; Endothelial Cells; Humans; SARS-CoV-2; Thalidomide | 2021 |
Assessing the Risk of Apremilast Use for Psoriasis During the COVID-19 Pandemic.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase III as Topic; COVID-19; Humans; Phos | 2021 |
COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast.
Topics: Administration, Oral; Adult; Aged; COVID-19; COVID-19 Vaccines; Female; Humans; Male; Middle Aged; O | 2021 |
The influence of leprosy-related clinical and epidemiological variables in the occurrence and severity of COVID-19: A prospective real-world cohort study.
Topics: Adrenal Cortex Hormones; BCG Vaccine; Brazil; Clofazimine; Cohort Studies; COVID-19; COVID-19 Drug T | 2021 |